Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ribupatide · KAI-9531

Peptide · developed by Kailera

Phase 3 Most advanced trial
KLRA Developer
1 Registered trials

What is Ribupatide?

Ribupatide (KAI-9531) is a drug studied in obesity and overweight in people with diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
KAI-9531
Drug type
Peptide
Therapy area
Metabolic
Developer
Kailera (KLRA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
58K8SFK97C

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07284901 Phase 3 Obesity With Diabetes Active not recruiting KLRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obesity With DiabetesOverweight With Diabetes

More from Kailera

Follow KLRA, the company behind Ribupatide

See KLRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KLRA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.